Inari Medical (NASDAQ:NARI – Free Report) had its price target increased by Piper Sandler from $52.00 to $80.00 in a report ...

Baird R W cut shares of Inari Medical (NASDAQ:NARI – Free Report) from a strong-buy rating to a hold rating in a research ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from ...

NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.

We recently compiled a list of the Investor Optimism Boosts Jump of These 10 Stocks. In this article, we are going to take a ...

Stryker plans to acquire Inari Medical for $4.9 billion to enhance its venous disease treatment portfolio. Inari, valued at nearly $3 billion, has seen increased interest amid growth in medical device ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular portfolio and boosts revenue growth by 50bp, with minimal ...

Inari Medical (NARI – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today. The company’s shares ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

The latest health news highlights Trump considering an executive order to protect gas stoves, warnings for GSK's and Pfizer's ...

Stryker acquires Inari Medical in a $4.9 billion deal, enhancing its vascular portfolio with innovative VTE treatments and a ...